Local TAT-p27Kip1 fusion protein inhibits cell proliferation in rat carotid arteries.

INTRODUCTION p27(Kip1) is a cyclin kinase inhibitor that induces cell cycle arrest. In this study, the efficacy of fusion protein TAT- p27(Kip1) to inhibit cell proliferation in rat perivascular injured carotid arteries was tested. METHODS The cDNA of p27(Kip1) and GFP (green fluorescein protein) fused to the TAT epitope, which allows cell penetration, yielded TAT-p27 (Kip1) and TAT-GFP fusion proteins. In vitro biological activity on cell proliferation was evaluated by [(3)H] thymidine DNA incorporation in rabbit aortic endothelial cells (REC). An in vivo model used a silicone collar filled with saline positioned around the carotid vessel for 14 days to produce an increased adventitia cross-sectional area. RESULTS TAT-p27(Kip1) inhibited REC proliferation in vitro using either 100, 200, and 500 nM compared to control (88.2 +/- 4.4, 81.3 +/- 7, 71.9 +/- 4.2 vs. 100 +/- 6.7%, N = 3, respectively, p < 0.05). This response was stable for purified proteins stored at -20*C for at least 23 days. In vivo , TAT-p27(Kip1) solution reduced adventitia cross-sectional area in a dose-dependent manner compared to TAT-GFP (area in mm(2) - TAT-p27(Kip1): 200 nM, 0.160 +/- 0.018; 500 nM, 0.050 +/- 0.005 vs. TAT-GFP: 500 nM, 0.595 +/- 0.066 vs. the contralateral: 0.047 +/- 0.005, N = 7, p < 0.01). CONCLUSION Taken together, these results provide evidence that TAT-p27(Kip1) can inhibit vascular cells proliferation. It is the first successful demonstration that the cell permeable TAT-p27(Kip1) has potential as a vascular anti-proliferative agent.

[1]  Victoria Del Gaizo Moore,et al.  Transactivator of Transcription Fusion Protein Transduction Causes Membrane Inversion* , 2004, Journal of Biological Chemistry.

[2]  James M. Roberts,et al.  p27Kip1 modulates cell migration through the regulation of RhoA activation. , 2004, Genes & development.

[3]  Kurt Ballmer-Hofer,et al.  Antennapedia and HIV Transactivator of Transcription (TAT) “Protein Transduction Domains” Promote Endocytosis of High Molecular Weight Cargo upon Binding to Cell Surface Glycosaminoglycans* , 2003, Journal of Biological Chemistry.

[4]  E. Snyder,et al.  Anti-cancer protein transduction strategies: reconstitution of p27 tumor suppressor function. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[5]  M. Johansson,et al.  Cell surface adherence and endocytosis of protein transduction domains. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

[6]  E. Kılıç,et al.  Intravenous TAT-GDNF Is Protective After Focal Cerebral Ischemia in Mice , 2003, Stroke.

[7]  A. Diez-Juan,et al.  Coordinate Control of Proliferation and Migration by the p27Kip1/Cyclin-Dependent Kinase/Retinoblastoma Pathway in Vascular Smooth Muscle Cells and Fibroblasts , 2003, Circulation research.

[8]  M. Pagano,et al.  Novel p27kip1 C-Terminal Scatter Domain Mediates Rac-Dependent Cell Migration Independent of Cell Cycle Arrest Functions , 2003, Molecular and Cellular Biology.

[9]  S. Futaki.  Arginine-rich peptides: potential for intracellular delivery of macromolecules and the mystery of the translocation mechanisms. , 2002, International journal of pharmaceutics.

[10]  A. Diez-Juan,et al.  Overexpression of p27Kip1 by doxycycline‐regulated adenoviral vectors inhibits endothelial cell proliferation and migration and impairs angiogenesis , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[11]  R. Schwartz,et al.  p27-p16 Fusion Gene Inhibits Angioplasty-Induced Neointimal Hyperplasia and Coronary Artery Occlusion , 2001, Circulation research.

[12]  S. Dowdy,et al.  TAT-mediated protein transduction into mammalian cells. , 2001, Methods.

[13]  S. Marx,et al.  Role for p27(Kip1) in Vascular Smooth Muscle Cell Migration. , 2001, Circulation.

[14]  K. Hruska,et al.  Protein transduction: unrestricted delivery into all cells? , 2000, Trends in cell biology.

[15]  E. Nabel,et al.  Differential effects of the cyclin-dependent kinase inhibitors p27(Kip1), p21(Cip1), and p16(Ink4) on vascular smooth muscle cell proliferation. , 2000, Circulation.

[16]  S. Schwarze,et al.  In vivo protein transduction: delivery of a biologically active protein into the mouse. , 1999, Science.

[17]  James M. Roberts,et al.  CDK inhibitors: positive and negative regulators of G1-phase progression. , 1999, Genes & development.

[18]  J. Schulte‐Mönting,et al.  Concordant upregulation of type II-TGF-beta-receptor, the cyclin-dependent kinases inhibitor P27Kip1 and cyclin E in human atherosclerotic tissue: implications for lesion cellularity. , 1999, Atherosclerosis.

[19]  S Marx,et al.  Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle. , 1999, Circulation.

[20]  Natalie A. Lissy,et al.  Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p27Kip1 induces cell migration , 1998, Nature Medicine.

[21]  E. Nabel,et al.  Expression of cyclin-dependent kinase inhibitors in vascular disease. , 1998, Circulation research.

[22]  P. Nisen,et al.  Downregulation of cyclin-dependent kinase 2 activity and cyclin A promoter activity in vascular smooth muscle cells by p27(KIP1), an inhibitor of neointima formation in the rat carotid artery. , 1997, The Journal of clinical investigation.

[23]  J. Venter,et al.  Hormone and neurotransmitter receptors in an established vascular endothelial cell line. , 1976, Proceedings of the National Academy of Sciences of the United States of America.

[24]  S. Marx,et al.  Role for p 27 Kip 1 in Vascular Smooth Muscle Cell Migration , 2001 .